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Aging leads to a gradual decline in physical activity and disrupted energy homeostasis. The
NAD+-dependent SIRT6 deacylase regulates aging and metabolism through mechanisms
that largely remain unknown. Here, we show that SIRT6 overexpression leads to a reduction
in frailty and lifespan extension in both male and female B6 mice. A combination of phy-
siological assays, in vivo multi-omics analyses and 13C lactate tracing identified an age-
dependent decline in glucose homeostasis and hepatic glucose output in wild type mice. In
contrast, aged SIRT6-transgenic mice preserve hepatic glucose output and glucose home-
ostasis through an improvement in the utilization of two major gluconeogenic precursors,
lactate and glycerol. To mediate these changes, mechanistically, SIRT6 increases hepatic
gluconeogenic gene expression, de novo NAD+ synthesis, and systemically enhances gly-
cerol release from adipose tissue. These findings show that SIRT6 optimizes energy home-
ostasis in old age to delay frailty and preserve healthy aging.
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Aging is associated with an overall decline in health,increased frailty and is a major risk factor for multiplechronic diseases1. Therefore, increasing our under-
standing of the mechanisms underlying aging processes is a top
priority to enable the development of interventions that will lead
to the preservation of health and improvements on survival/
lifespan.
A growing body of evidence indicates that diet and metabolism
are key targetable regulators of healthy lifespan2. Dietary
restriction (DR), a reduced calorie intake without malnutrition
(calorie restriction, CR), as well as some fasting regimens, provide
profound health benefits and lead to lifespan extension3–5.
Similarly, pharmacological or genetic inhibition of the major
nutrient-abundance-sensing signaling pathways, mammalian
target of rapamycin (mTOR) and insulin/IGF-1, were shown to
improve lifespan in organisms ranging from yeast to mammals6.
Likewise, activation of pathways which sense a low-energy state,
such as AMP kinase (AMPK) and sirtuins lead to increased
longevity in a wide range of organisms6.
Previous studies have shown a loss of metabolic homeostasis
with aging. At the level of the whole organism, aged mice and
humans show changes in energy expenditure and metabolic
flexibility7,8. At the cellular level, aging affects various metabolic
pathways, many of which are associated with a decline in mito-
chondrial function8,9. Notably, the levels of key metabolites that
are consumed by cells for energy production, such as glucose,
amino acids (AAs), and lipids, are altered with age in the circu-
lation and in tissues7,10. Yet, despite such extensive studies, a
comprehensive description of age-related metabolic alterations is
lacking. Moreover, it is still unclear why the ability to maintain
energy homeostasis is lost with age. The age-dependent changes
in metabolite abundance together with the decline in mitochon-
drial function9, suggest a global decrease in energy production
with age. Interestingly, many of the aforementioned interventions
that promote longevity also activate mitochondrial function and
energy metabolism11, suggesting that enhancing energy produc-
tion may be beneficial for extending healthy lifespan.
An essential metabolic process for providing energy to the
body is gluconeogenesis (GNG). GNG, the de novo synthesis of
the body’s primary source of fuel, glucose, from non-
carbohydrate precursors, occurs mainly in the liver, and to a
lesser extent in the kidney and gastrointestinal tract. This process
is necessary for maintaining blood glucose during fasting and
physical activity, and contributes ~64% of total glucose produc-
tion even during the first 22 h of fasting in humans12. GNG is
regulated through complex pathways, which include extra- and
intra-hepatic mechanisms13. Given the major role of GNG in
energy production, one would expect GNG to play a major role in
aging and frailty. Yet, the effect of age on GNG capacity in
mammals is unclear, and reported studies were mostly performed
in cell culture. While some studies showed an increase in GNG
capacity with age14, others reported a decrease15–17. These con-
tradictory findings can stem from different experimental systems
or gluconeogenic precursors used. Thus, an extensive examina-
tion of the effect of aging on energy production and GNG, and its
potential connection to age-associated frailty, is required.
Sirtuins are nicotinamide adenine dinucleotide (NAD+)-depen-
dent protein deacylases and mono-ADP-ribosyl transferases, which
are highly conserved from yeast to mammals. Sirtuins were impli-
cated in many cellular pathways, including DNA repair, metabo-
lism, inflammation, cancer, and aging18. Of the seven mammalian
sirtuins, SIRT1-7, SIRT1, and SIRT6 protein levels increase upon
dietary restriction and fasting in various mouse tissues and human
cell lines19–21. While most SIRT1 knockout (KO) mice die peri-
natally, in a few weeks age22,23, 129svJ background SIRT6 KO mice
exhibit severe developmental defects but survive to about 4 weeks of
age24. Similarly, in humans and primates, mutations resulting in
SIRT6 inactivation result in prenatal or perinatal lethality accom-
panied by severe developmental brain defects25. Interestingly,
whole-body SIRT1 overexpression in mice leads to improvement in
parameters reflecting healthspan, but not lifespan26. Whereas
whole-brain-specific SIRT1 overexpression did not affect lifespan
and brain plasticity, hypothalamic SIRT1 overexpression delays
aging27,28. However, whole-body SIRT6 overexpression in the
mixed-CB6 mouse background leads to a significant extension of
male lifespan and healthspan, associated with inhibition of IGF-1
signaling29,30.
A significant amount of data demonstrate the major role of
SIRT6 in metabolism31. SIRT6 represses glycolysis in an HIF1α-
dependent manner32, thereby acting as a tumor suppressor by
inhibiting the Warburg effect33. Liver-specific deletion of SIRT6
results in increased glycolysis, triglyceride synthesis, reduced β-
oxidation, and fatty liver formation34. Similarly, SIRT6 hetero-
zygotic mice show significantly reduced PPARα-induced β-
oxidation35. Liver-specific SIRT6 induction showed that SIRT6
negatively regulates GNG by regulating PGC1α and FOXO1
activities36,37. However, Deng and his colleagues34 showed no
effect of liver-specific SIRT6 KO on GNG. Importantly, these
metabolic roles of SIRT6 were determined in young mice. Thus,
given SIRT6’s major role in aging, the broader metabolic role of
SIRT6 under fasting as well as the effect of SIRT6 overexpression
on metabolism in the context of aging should be described.
Here, we show that overexpression of SIRT6, but not SIRT1,
extends lifespan in C57BL/6JOlaHsd mice in both sexes. Over-
expression of SIRT6 reduced the age-related metabolic decline in
energy metabolism pathways and inhibited frailty by preserving
hepatic NAD+ levels, GNG capacity, and maintenance of nor-
moglycemia, key markers of healthy aging. These results
emphasize the potential of targeting SIRT6 for maintaining
energy metabolism and reducing age-related frailty.
Results
SIRT6, but not SIRT1, regulates lifespan in C57BL/6JOlaHsd
mice in both sexes. To explore the role of SIRT6 and its inter-
action with SIRT1 in aging, the lifespan of SIRT1-, SIRT6-, and
SIRT1+ SIRT6-overexpressing C57BL/6JOlaHsd transgenic (tg)
male and female mice were compared to their wild-type (WT)
littermates. Previously we showed that SIRT6 overexpression in
mixed-CB6 background extend only male lifespan29. As depicted
in Fig. 1a, SIRT6 overexpression in C57BL mice led to a 27% and
15% extension in median lifespan, in males and females, respec-
tively (p= 7.1 × 10−6 and 1.1 × 10−6). Likewise, in comparison to
their WT littermates, SIRT6 overexpression induced a 11% and
15% extension in maximal lifespan in males and females, respec-
tively (p= 0.007 and 0.001). Similarly, SIRT1+ 6-tg mice exhib-
ited a 25% and 20% extension in median lifespan (p= 1.1 × 10−6
and 1.2 × 10−8), and 13% and 15% extension in maximal lifespan
(p= 0.01 and 0.001), in males and females, respectively. Relative to
WT littermates, overexpression of SIRT1 alone did not affect
median or maximal lifespan, in accordance with previous data26.
However, SIRT1-tg mice did show improved survival when com-
paring the 20th percentile in transgenic versus WT (p= 0.01 on
pooled sexes). Thus, although SIRT1 may have some beneficial
effects on early-age healthspan, SIRT6, but not SIRT1, regulates
lifespan in C57BL/6JOlaHsd mice independent of sex, and SIRT1
does not synergize with SIRT6 to further increase median or
maximal survival.
SIRT6 improves healthspan in aged mice. We therefore con-
tinued our study of SIRT6, to determine the mechanism(s) for the
effects on lifespan. SIRT6 possesses tumor suppressor activity33.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23545-7
2 NATURE COMMUNICATIONS |         (2021) 12:3208 | https://doi.org/10.1038/s41467-021-23545-7 | www.nature.com/naturecommunications
Thus, we first sought to assess whether this activity contributes to
the prolonged lifespan of SIRT6 and SIRT1+ 6 genotypes. At
25 months of age, SIRT1+ 6-tg mice exhibited significantly fewer
neoplasms (Fig. 1b). No difference in neoplasm incidence was
observed at time of natural death, indicating that SIRT1+ 6-tg
mice develop neoplasms significantly later at life, but ultimately
die with similar neoplastic load. A similar trend was observed in
















































































































































































































































Fig. 1 SIRT6 regulates lifespan and healthspan of C57BL/6JOlaHsd mice of both sexes. a Kaplan–Meier survival curves for male, female, and combined
sexes of WT (n= 52 males, n= 50 females), SIRT1-tg (n= 47 males, n= 30 females), SIRT6-tg (n= 51 males, n= 41 females), and SIRT1+ 6-tg (n= 47
males, n= 44 females) mice. p-values for SIRT6-tg vs. WT mice are shown and were derived from two-tailed log-rank calculations. Median lifespan for
each genotype is shown in parentheses. b–d Neoplasia (b), cancer (c), and gastrointestinal adenoma (d) incidence at the age of 25 months. For (b–d), n=
16 mice per genotype, a mixture of both sexes. Two-tailed Fisher’s exact test; *p < 0.05 vs. WT. Exact p-values are reported in Supplementary Table 1. e
Respiratory exchange ratio (RER) averaged over 3 days in young and old WT and SIRT6-tg mice from either sex measured every half-hour. Three-way
ANOVA with repeated measures with age, genotype, and time as variables. Sidak’s post hoc; young WT (* in blue) or old SIRT6 (* in green) vs. old WT. n
= 8 mice per group, except for young SIRT6 where n= 7 mice. f Spontaneous wheel running activity of males at the ages of 8 months (n= 8 mice per
genotype) and 15 months (n= 9 mice for WT, SIRT1, SIRT6, n= 7 mice for SIRT1+ 6). Two-way ANOVA with time and genotype as variables. g Exercise
ability on treadmill in young and old males. Two-way ANOVA with Sidak’s post hoc. n= 6 mice per group, except for young WT where n= 5 mice. *p <
0.05, **p < 0.01, ***p < 0.001. In (e) and (f), values are shown as mean ± SEM. In (g), box extends from the 25th to 75th percentiles, line in the middle of
the box is the median and whiskers go down to the smallest value and up to the largest. For (e–g), exact p-values are reported in the Source Data file.
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incidence was similar between genotypes at the time of natural
death, and non-significantly lower in SIRT6 and SIRT1+ 6-tg
mice at 25 months of age (Fig.1c and Supplementary Fig. 1b).
Nevertheless, the prevalence of gastrointestinal adenomas was
significantly lower in SIRT6-tg and SIRT1+ 6-tg mice both at
25 months of age and at natural death (Fig. 1d and Supplemen-
tary Fig. 1c). Most other pathologies analyzed did not differ
between genotypes, although some inflammatory and degen-
erative processes were significantly less common in the transgenic
mice (see Supplementary Table 1). Collectively, as previously
suggested29, autopsy results indicate that cancer onset might be
delayed in long-lived SIRT6-tg and SIRT1+ 6-tg mice.
Next, we determined various healthspan parameters in mice of
different age groups. No significant difference in weight was found
between various genotypes, up to 1 year of age. After the age of 1
year, in comparison to WT littermates, SIRT6-tg and SIRT1+ 6-
tg mice were slightly heavier (4–7% increase), independent of sex
(Supplementary Fig. 1d), with increased fat percentage in SIRT6-
tg mice (Supplementary Fig. 1e). Importantly, female SIRT6-tg
and SIRT1+ 6-tg preserved body weight in advanced age, which is
independently associated with increased survival in mice and
humans38,39 (Supplementary Fig. 1d, f).
In mice and humans, anemia is a common age-related chronic
condition40,41. Aged WT mice had lower red blood cell (RBC)
count, hematocrit (Hct), hemoglobin (Hb), and mean corpuscular
hemoglobin concentration (MCHC). Interestingly, all these
parameters remained higher in old SIRT6-tg mice, at levels
similar to those in young WT mice (Supplementary Fig. 1g and
Supplementary Table 2). Moreover, platelet count significantly
increased in aged mice, but was maintained at low levels in old
SIRT6-tg mice (Supplementary Fig. 1g). Blood chemistry analyses
showed that LDL/HDL ratio increased with age, yet remained low
in SIRT6-overexpressing animals (Supplementary Fig. 1h). In
addition, serum albumin, which is essential for maintenance of
blood osmotic pressure and as a carrier for various blood factors
and nutrients such as fatty acids, was significantly higher in
SIRT6-tg compared to WT independent of age (Supplementary
Fig. 1h). Finally, serum IGF-1 levels, lower levels of which are
associated with increased lifespan, were lower in SIRT6 and
SIRT1+ 6-tg, but not in SIRT1-tg mice, independent of sex
(Supplementary Fig. 1i). Other blood parameters analyzed did not
differ between genotypes (Supplementary Tables 2 and 3).
Altogether, SIRT6 overexpression significantly improved a large
set of blood healthspan markers.
Metabolic dysfunction is a hallmark of aging42. Thus, whole-
body in vivo metabolism was followed in young and old mice
using metabolic cages. Food intake increased with age in females
but was similar between genotypes irrespective of age (Supple-
mentary Fig. 2a). In comparison to old mice, young mice showed
higher metabolic flexibility, seen by circadian fuel source switch
from carbohydrate to fatty acids, as measured by the respiratory
exchange ratio (RER). Interestingly, old SIRT6-tg mice main-
tained a young-like oscillatory RER pattern (Fig. 1e and
Supplementary Fig. 2b). The change in RER was primarily seen
during the light-phase, indicating that SIRT6 overexpression
overcomes an age-dependent defect in daily transition from
carbohydrate to fat oxidation. O2 consumption and CO2
production (normalized to body weight) decreased with age in
males, but not in females, with no effect of genotype
(Supplementary Fig. 2c, d).
Physical activity is a main criterion in the frailty index of aged
mice and is clinically relevant to human aging43. Thus, selected
physical-activity parameters were compared between genotypes,
including in-cage locomotor, rearing activities, and spontaneous
wheel and forced treadmill running. With age, WT male mice
showed unchanged locomotor and rearing activities, but a
significant reduction in spontaneous wheel and forced treadmill
running (Fig. 1f, g and Supplementary Fig. 2e–g, i). Female mice
showed an age-dependent reduction in running wheel activity
(Supplementary Fig. 2g). Strikingly, in males, SIRT6 overexpres-
sion repressed this age-dependent decline in physical activity. In
comparison to 15 months old WT male littermates, SIRT6-tg and
SIRT1+ 6-tg male mice ran significantly longer distances and
spent more voluntary time on the running wheel (Fig. 1f and
Supplementary Fig. 2h). SIRT1+ 6-tg average and maximal
running speeds were significantly higher (Supplementary Fig. 2h).
At the older age of 22 months, the wheel activity of SIRT6 and
SIRT1+ 6-tg mice was still maintained higher than WT
littermates (Supplementary Fig. 2g). SIRT6 overexpression in
male mice also protected against the age-related decline in
treadmill performance, as running duration and distance traveled,
and overall amount of work performed were significantly higher
in old SIRT6-tg and SIRT1+ 6-tg mice relative to old WT
littermates (Fig. 1g and Supplementary Fig. 2i). No difference in
treadmill performance was found between SIRT1-tg mice and
WT littermates. Young female SIRT6-tg mice showed a non-
significant increase in in-cage locomotor and rearing activities,
with no change in spontaneous wheel or forced treadmill running
at old age (Supplementary Fig. 2e–g, j). Taken together,
overexpression of SIRT6 alone or with SIRT1 significantly
improves healthspan, promotes physical activity performance,
and reduces frailty at old age.
SIRT6 affects GNG and tricarboxylic acid (TCA) cycle-related
serum metabolites during fasting. Surprisingly, despite the
extensive research on the metabolic roles of SIRT1 and SIRT6,
little is known about their impact at the in vivo metabolite levels.
Thus, serum metabolomics was performed in 15 months old mice
from the four genotypes in the fed state, and after 4 and 16 h
fasting. Principal component analysis (PCA) of all identified
metabolites showed that fasting profoundly shifted the serum
metabolome as early as after 4 h (Supplementary Fig. 3a). Nota-
bly, fasting increased the levels of circulating free fatty acids
(FFAs) and β-hydroxybutyrate, likely due to activation of lipolysis
and ketogenesis. In contrast, multiple circulating AAs, including
the branched chain amino acids (BCAAs) isoleucine and valine,
were depleted upon fasting, likely due to depletion of dietary AAs
(Fig. 2a and Supplementary Fig. 3b, c; see also Supplementary
Table 4 for source data). During fasting, levels of these BCAAs
were significantly lower in the mice overexpressing SIRT1, SIRT6,
or both (Fig. 2b). WT mice show a reduction in serum glucose
levels between 4 and 16 h of fasting. Interestingly, SIRT6, but not
SIRT1, overexpression suppressed this response (Fig. 2c). These
findings indicate that compared to WT mice, SIRT6-tg mice are
more efficient in maintaining blood glucose levels during fasting.
Maintaining higher glucose levels during fasting in SIRT6-tg
suggest higher GNG in these mice. Glycerol, lactate, pyruvate,
and alanine are the main gluconeogenic substrates. SIRT6
overexpression led to significantly higher serum glycerol levels
at 16 h fast, which correlated positively with serum glucose levels
(Fig. 2c and Supplementary Fig. 3e). In contrast, at the age of
15 months, no significant effect for either genotype was found on
lactate, pyruvate, and alanine levels upon fasting, with the
exception of increased lactate levels in SIRT1+ 6-tg mice at 4 h
fast (Fig. 2c and Supplementary Fig. 3d, e). The serum levels of
the tricarboxylic acid (TCA) cycle metabolites α-ketoglutarate
(αKG), malate, and citrate increased in SIRT6 and SIRT1+ 6-tg,
but not in SIRT1-tg, mostly at the 4 h fast (Fig. 2d). Thus, serum
metabolomics shows that normoglycemia maintenance and TCA
cycle are affected by SIRT6, but not by SIRT1 overexpression.
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SIRT6 restores age-related deterioration in normoglycemia
and GNG capacity. To further explore the normoglycemic effect
of SIRT6, blood glucose levels were measured in young and old,
fed or fasted mice after 0, 4, 8, 12, 16, and 24 h of fasting. In
young WT mice, a gradual increase in blood glucose levels was
found between 4 and 12 h of fasting, followed by a significant
decrease until 24 h of fasting. Interestingly, 22 months old WT
animals were not able to maintain glucose levels, as blood glucose
started to decrease earlier, reaching a significant decrease already
after 8 h of fasting (Fig. 3a). Strikingly, glucose levels in old
SIRT6-tg mice resembled those of young-WT mice during this
fasting period (Fig. 3a). The effect of SIRT6 on preserving nor-
moglycemia during fasting was not sex specific, as similar results
were seen in females (Fig. 3b). Additionally, at this age of
22 months, SIRT1+ 6 animals presented the same phenotype as
the SIRT6-tg (Supplementary Fig. 4a). Last, compared to young
WT, young SIRT6-tg attained higher blood glucose levels. Thus,
SIRT6 overexpression blocks the significant age-dependent
impairment of normoglycemia and maintains young-like blood
glucose levels even at advanced age.
We then hypothesized that SIRT6 may reverse the impaired
glucose regulation observed in old mice by activating glycogen-
olysis and/or gluconeogenesis. After 4 h morning fast, hepatic
glycogen levels were similar between genotypes in young mice
and higher in old SIRT6-tg mice relative to WT littermates,
suggesting net activation of glycogenesis, but not glycogenolysis,
in old SIRT6-tg livers (Supplementary Fig. 4b). Consequently, we
determined GNG capacity by measuring blood glucose after
injection of lactate or glycerol, major gluconeogenic precursors, in
young and old mice. In accordance with the glycemic pattern,
gluconeogenic capacity from both precursors significantly
decreased in old WT male mice but was maintained in old
SIRT6-tg male mice at similar levels as in young WT mice
(Fig. 3c, d). This effect was independent of sex since similar results
were obtained in females (Fig. 3e, f). Likewise, old SIRT1+ 6-tg
animals showed a significant increase in GNG capacity from
lactate and glycerol at old age (Supplementary Fig. 4c, d).
Importantly, glucose tolerance was similar between young and old
WT mice and SIRT6-tg mice of both sexes (Supplementary Fig. 4e,
f), indicating that the effect could not be attributed to faster
glucose clearance in the aged WT mice. Altogether, these results
show that SIRT6 overexpression leads to maintenance of young-
like GNG in old age due to improved glycerol and lactate
utilization under fasting.
SIRT6 promotes hepatic catabolic and anti-inflammatory













































































































































































































































































































































































Fig. 2 Serum metabolites associated with fasting and sirtuin overexpression. a Heatmap showing serum metabolites from key metabolic pathways that
changed significantly either with dietary state (fed, and 4 h and 16 h of fasting), genotype, or both as measured in two-way ANOVA. Each square
represents average metabolite abundance of 7 WT mice, 7 SIRT1-tg mice, 6 SIRT6-tg mice, and 5 SIRT1+ 6-tg mice. b–d Scatterplots of data from (a)
showing the levels of BCAAs (b), glucose and the GNG precursors glycerol and lactate (c), and TCA cycle metabolites (d). For (b–d), n= 7 WT mice, n= 7
SIRT1-tg mice, n= 6 SIRT6-tg mice, and n= 5 SIRT1+ 6-tg mice. Box extends from the 25th to 75th percentiles, line in the middle of the box is the median
and whiskers go down to the smallest value and up to the largest. Statistical analysis was performed using two-way ANOVA (time, genotype) with
Dunnett’s post hoc correction. p-value for genotype or fasting effect is indicated in graphs, exact p-values are reported in Supplementary Table 4. *p < 0.05,
**p < 0.01.
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hepatic pathways that are associated with the restored gluco-
neogenic capacity, liver RNA sequencing of 4 h-fasted 6 months
old WT and SIRT6-tg male and female mice was performed
(Supplementary Table 5). PCA showed that gender was respon-
sible for most of the variance (PC1). In addition, a striking
genotype effect was seen in PCA, with the effect of
SIRT6 substantially greater in males than females (Fig. 4a). Using
Gene Set Enrichment Analysis (GSEA), we found that inflam-
matory pathways were significantly inhibited in SIRT6-tg males,
whereas a similar but milder effect was seen in females (Fig. 4b
and Supplementary Table 6). Suggesting that the observed dif-
ference in the effects of SIRT6 on lifespan between sexes (Fig. 1a)
might stem from its transcriptional regulation.
Metabolism, enriched for catabolic pathways, was strongly up-
regulated in both male and female SIRT6-tg mice (Fig. 4b and
Supplementary Table 6). Fatty-acid β-oxidation, TCA cycle,
aerobic respiration, and AA catabolism gene expression were
significantly increased in SIRT6-tg mice (Fig. 4c). These findings
suggest that SIRT6 induces fatty acid and AA catabolism in the
liver, mimicking the effect of fasting and CR in both mice and
primates44–46. Analysis of upstream regulators, common to both
male and female transcriptomes, showed that PPARα, a nuclear
receptor which promotes fatty-acid β-oxidation in the liver44 was
activated (Fig. 4d). Importantly, the SIRT6-dependent increased
expression of key catabolic genes of β-oxidation, TCA cycle, and
aerobic respiration, was also maintained at old age (Fig. 4e). In
agreement with the effect of SIRT6 on GNG capacity, the
expression of the key hepatic GNG genes Pck1, Pcx, G6pc, and
Fbp1 was higher in SIRT6-tg livers (Fig. 4e). Likewise, the
expression of the transcriptional coactivator Ppargc1a, which
regulates gluconeogenic gene expression and mitochondrial
biogenesis, was also increased in old SIRT6-tg. In agreement
with this finding, hepatic mitochondrial DNA (mtDNA) content
was higher in SIRT6-tg mice (Fig. 4e).
Next, to explore the effect of SIRT6 on protein levels, a
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Fig. 3 SIRT6 overexpression blocks age-dependent normoglycemia and deterioration in gluconeogenesis capacity. a Blood glucose levels in young and
old WT (blue) and SIRT6-tg (green) male mice at fed and fasted time points, as indicated in the graph. n= 10 young WT mice, n= 8 young SIRT6 mice, n
= 7 old WT and old SIRT6 mice. b Same as (a), but in females. n= 8 young WT mice, n= 7 young SIRT6, old WT, and old SIRT6 mice. c Lactate tolerance
test in 6 h-fasted male mice; n= 6 young WT, old WT, and old SIRT6 mice, n= 5 young SIRT6 mice. d Glycerol tolerance test in 6 h-fasted male mice; n=
6 mice per group. e Lactate tolerance test in 6 h-fasted female mice; n= 6 old WT, young SIRT6, and old SIRT6 mice, n= 7 young WT mice. f Glycerol
tolerance test in 6 h-fasted female mice; n= 6 young WT and young SIRT6 mice, n= 8 old WT mice, n= 9 old SIRT6 mice. The area under the curve
(AUC) for each tolerance test is shown on the right. For all panels, ages were 4–6 (young) and 22–24 (old) months. Statistical significance was calculated
using three-way ANOVA with Sidak’s post hoc for line graphs, and two-way ANOVA with Fisher’s LSD method for bar graphs. Young WT (* in blue) or old
SIRT6 (*in green) vs. old WT. In all panels, values are mean ± SEM. Exact p-values are reported in the Source Data file. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001.
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male mice utilized for RNA-seq was performed. Liquid
chromatography-tandem mass spectrometry (LC-MS/MS) analy-
sis identified and quantified 2785 hepatic proteins. PCA of the
proteomics data revealed that groups were clustered by genotype
(Supplementary Fig. 5a). The global transcriptome correlated well
with the proteome (r= 0.59, p < 0.0001; Supplementary Fig. 5b).
From the total expression list, 185 proteins were differentially
expressed between genotypes (Benjamini-Hochberg corrected p <
0.05 with ±20% fold change), of which 122 and 63 were down-
and up-regulated, respectively, in SIRT6-tg mice (Supplementary
Fig. 5c and Supplementary Table 7). In agreement with
transcriptomics data, SIRT6 up-regulated proteins were enriched
for metabolic-related pathways, whereas down-regulated proteins
included immune-related pathways (Supplementary Fig. 5d).
Interestingly, proteomics analysis also identified a significant
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subunits PA28α and PA28β and core subunits β2i and β5i in
SIRT6-tg mice. In addition, the β5 constitutive proteasome (c-
proteasome) subunit was significantly increased in SIRT6-tg livers
(Supplementary Fig. 5e, f). Previous studies showed a role for the
i-proteasome in regulating aging. A mouse model with reduced
β5 proteasomal activity accumulates ubiquitinated (Ub) proteins
and has shortened lifespan47, whereas overexpression of β5 in
Drosophila melanogaster reduces Ub-protein aggregates and
increases lifespan48. Similarly, we found significantly decreased
Ub-protein levels (Supplementary Fig. 5g), suggesting SIRT6 as a
key regulator of protein homeostasis (proteostasis). Altogether,
hepatic transcriptomic and proteomic profiling revealed the
SIRT6-dependent activation of catabolic and anti-inflammatory
pathways, which can potentially support the activated GNG
(Supplementary Fig. 5h).
Young-like hepatic TCA cycle and GNG-related metabolite
abundance in old SIRT6-tg mice. To further understand the
liver metabolic profile of SIRT6 in normoglycemia and GNG
during aging, liver metabolomics was performed on young and
old 6 h-fasted WT and SIRT6-tg mice. Aging had a profound
effect on liver metabolite abundance. Out of 125 identified
metabolites, 45 were significantly different between young and
old WT mice, and 33 between young and old transgenic mice.
Genotype also had a significant effect, as 16 metabolites in young
animals and 9 metabolites in aged animals significantly differed
between WT and SIRT6-tg. Together, a total of 70 significant
metabolites were altered by age or genotype (Fig. 5a and Sup-
plementary Table 8). Metabolite Set Enrichment Analysis
(MSEA) showed that TCA cycle, mitochondrial electron trans-
port chain, and GNG were affected by age in both WT and
transgenic mice. Genotype also affected these three pathways in
either young or old mice (Supplementary Fig. 6a). Interestingly,
PCA on significant metabolites showed that old SIRT6-tg
grouped closer to the younger profile (Fig. 5b). These findings
indicate that SIRT6 maintains a global young-like metabolite
profile in the liver.
Next, significant metabolites were organized based on their
corresponding pathways (Fig. 5c and Supplementary Fig. 6b).
Interestingly, similar to blood glucose levels (Fig. 3a), hepatic
glucose abundance decreased with age and tended to increase in
SIRT6-tg (Fig. 5d). The GNG intermediates glucose-6-phosphate
(G6P) and fructose-6-phosphate (F6P) both increased with age,
but in aged SIRT6-tg mice, they remained at young-like levels
(Fig. 5d). These results are consistent with our findings that
SIRT6 blocks the aging-associated decrease in hepatic GNG.
We next examined TCA cycle metabolite levels. SIRT6
overexpression inhibited the age-related decline in the concen-
trations of citrate and cis-aconitate. Additionally, it significantly
increased the levels of αKG at young age and malate at old age
(Fig. 5e). Of note, citrate activates the key GNG enzyme fructose-
1,6-bisphosphatase (FBP1)49, suggesting that higher citrate levels
can support GNG by activating FBP1. The GNG substrates
lactate, pyruvate, and glycerol and numerous AAs that replenish
the TCA cycle (Ser, Met, Tyr, Trp, Thr, Leu, and Ile) were
depleted in the aged liver (Fig. 5c and Supplementary Fig. 6b–d).
In comparison to young WT, young SIRT6-tg has higher
pyruvate, glycerol, and poly-unsaturated fatty acid (PUFA) levels.
However, old WT and SIRT6-tg have similar levels of these
(Fig. 5c and Supplementary Fig. 6b, c, h). Old SIRT6-tg liver
shows a trend towards higher AA levels than old WT liver. This
elevation might be due to an increased autophagy in old SIRT6-tg
mice. Indeed, in comparison to WT liver, SIRT6-tg liver shows a
significant increase in autophagy levels as measured by the
autophagy markers LC3b-II and p62 (Supplementary Fig. 6i).
Importantly, the glucogenic AA serine was significantly higher in
old SIRT6-tg liver, similar to the levels found in young WT liver
(Supplementary Fig. 6d). These results suggest that TCA cycle
and GNG activities decrease in the aged liver due to decreased
levels of their precursors, and that SIRT6 might activate these
pathways by increasing their precursor levels.
Other metabolites also showed young-like levels in old livers
from aged SIRT6-tg mice. The abundance of the major β-
oxidation precursors, palmitoyl-carnitine and myristoyl-carnitine
increased with aging in old WT mice, but not in old SIRT6-tg
mice (Supplementary Fig. 6e). In addition, the disaccharide
trehalose, known to extend the lifespan of the nematode
Caenorhabditis elegans50, was depleted in aged WT, but not in
aged SIRT6-tg mice (Supplementary Fig. 6f). Likewise, SIRT6-tg
mice showed a lower age-dependent reduction in IMP levels
(Fig. 5c and Supplementary Fig. 6g). Thus, SIRT6 overexpression
inhibits additional aging-related phenomena.
SIRT6 maintains NAD+ levels and increases de novo NAD+
synthesis gene expression. Functional redox metabolism, mediated
by NAD+ and flavin adenine dinucleotide (FAD), is critical for
multiple metabolic reactions and is impaired by aging51. Interest-
ingly, hepatic NAD+ and FAD levels decreased with age. Remark-
ably, SIRT6 overexpression prevented the age-related decline of
NAD+ and FAD (Fig. 5f). In addition, nicotinamide (NAM), a
product of SIRT6 reaction and an NAD+ salvage precursor, also
decreased with age, and increased in SIRT6-tg, independently of age
(p genotype < 0.05; Fig. 5f). The maintained NAD+ levels in old
SIRT6-tg livers could be due to either reduced consumption or
increased production of NAD+. The DNA-damage-induced poly
[ADP-ribose] polymerase 1 (PARP1) is a major NAD+ consumer52.
Thus, we first tested the possibility that SIRT6 affects NAD+ con-
sumption by reducing DNA-damage-induced activation of PARP1.
However, we found that hepatic PARP1 levels, global PARylation,
and gamma-H2AX levels were similar between genotypes
Fig. 4 SIRT6 activates hepatic mitochondrial catabolic and anti-inflammatory pathways. RNA-seq was carried out on the liver of 6 months old WT and
SIRT6-tg mice from either sex. a Principal component analysis was performed on all expressed genes. Each data point represents an individual mouse. b
Gene Set Enrichment Analysis showing the top pathways up- or down-regulated in SIRT6-tg mice, sorted by normalized enrichment scores (NES). FDR q-
values are shown in orange. Pathways related to catabolism and to inflammation are presented in blue and red, respectively. c Four metabolic pathways up-
regulated in livers from male SIRT6-tg mice. In the upper part, each vertical black bar represents a gene in the gene set and its corresponding location in the
sorted gene list. In the lower part, corresponding heatmaps show the expression values of the top genes in each pathway, which contribute most to the
NES. High expression is colored in red and low expression in blue. Bold text indicates genes validated by qPCR in (e). d Ingenuity upstream regulator
analysis common to males and females, based on genes differentially expressed between WT and SIRT6-tg mice. p-values for PPARα are shown, calculated
by Fisher’s exact test. e Real-time PCR validation of gene expression from the indicated pathways, and mtDNA content in the livers of young and old WT
and SIRT6-tg males. Two-way ANOVA with Fisher’s LSD method, asterisks indicate values significantly different between WT and SIRT6-tg at the same
age. n= 8 mice per group, except for old SIRT6 for Coq10a (n= 6) and G6pc (n= 7), and for young WT and young SIRT6 for mtDNA content (n= 6). Mice
ages are 6 and 25 months. RQ, relative quantity. Bars represent mean ± SEM. Exact p-values are reported in the Source Data file. *p < 0.05, **p < 0.01, ***p
< 0.001, ****p < 0.0001.
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(Supplementary Fig. 6j), suggesting that SIRT6 does enhance NAD+
levels by reducing its consumption by PARP1. Next, we sought to
determine whether SIRT6 affects NAD+ production. Supplementing
mice with NAM results in increased expression of de novo NAD+
biosynthetic enzymes53. In accordance with their higher NAM
levels, the hepatic mRNA expression of multiple de novo NAD+
biosynthetic genes; Ido2, Tdo2, Haao, and Nmnat1 was up-regulated
in SIRT6-tg (Fig. 5g). In agreement, NMNAT1 and TDO2 protein
levels were also significantly increased in old SIRT6-tg livers
(Fig. 5h). These findings suggest that SIRT6-tg mice maintain NAD
+ levels during aging due to increased NAD+ production. Collec-
tively, liver metabolomics showed that SIRT6-tg mice present a
young-like profile of key metabolites of GNG, TCA cycle, and redox
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increased in SIRT6-tg, at least partially, by augmented NAD+
cofactor and glycerol/pyruvate substrate availability.
SIRT6 restores the aging-associated decline in hepatic lactate
oxidation. With age, WT mice showed reduced GNG capacity
even when supplemented with exogenous GNG precursors such
as lactate and glycerol (Fig. 3c, d). Thus, the age-dependent GNG
decline cannot be explained solely by limitations in substrate
availability. To further understand the mechanism underlying the
age-dependent reduction in GNG, in vivo stable isotope tracing
using uniformly labeled 13C lactate was performed (Fig. 6a). We
chose lactate, as its oxidation contributes carbons to both GNG
and the TCA cycle54,55, two pathways that were affected by aging
and SIRT6 (Figs. 2–5). [U-13C]-lactate was injected into 6 h-fas-
ted young and old WT and SIRT6-tg mice, followed by analysis of
liver metabolite isotopologue abundances 15 min after injection.
Total lactate concentrations and fractional abundance of its M+
3 isotopologue (lactate labeled on all 3 carbons) were similar
between groups in plasma and liver (Supplementary Fig. 7a, b).
These findings indicate that lactate transport into the liver is not
affected by aging or by SIRT6. Lactate oxidation resulted in
extensive labeling of liver pyruvate, alanine, TCA cycle metabo-
lites, and AAs that are derived from the TCA cycle (Glu, Gln,
Asp, Asn) (Supplementary Fig. 7c). Importantly, liver glucose was
also labeled, providing a direct evidence for lactate-derived
hepatic GNG (Fig. 6b). In comparison to WT mice, liver glucose
abundance was higher in SIRT6-tg following lactate administra-
tion in an age-independent manner (Fig. 6b). In young mice, no
significant differences were found in the abundance of labeled
pyruvate [M+ 3], TCA cycle metabolites αKG, succinate and
malate [M+ 2], or glucose [M+ 2, M+ 3], between genotypes
(Supplementary Fig. 7d). Interestingly, steady-state levels of
labeled glucose [M+ 2 to M+ 6], and most notably, glucose M+
2 and M+ 3 isotopologues significantly decreased in aged WT
mice, while remaining higher in old SIRT6-tg (p= 0.06 and 0.11,
respectively; Fig. 6c and Supplementary Fig. 7e). Labeling of the
TCA cycle intermediates αKG, succinate, and malate significantly
decreased with age in WT mice but remained higher in SIRT6-tg
mice (Fig. 6d). Thus, direct incorporation of lactate’s carbons to
the TCA cycle and to GNG deteriorates with age in WT mice but
is rescued in old SIRT6-tg mice.
In liver, when there is excess lactate or upon GNG induction,
lactate dehydrogenase (LDH) catalyzes the reversible conversion
of NAD+-dependent lactate to pyruvate. With age, a significant
reduction in total pyruvate and pyruvate M+ 3 levels was found
after [U-13C]-lactate injection (Fig. 6e). Interestingly, in compar-
ison to old WT mice, total pyruvate and pyruvate M+ 3 levels
were higher in old SIRT6-tg mice (Fig. 6e and Supplementary
Fig. 7c). These findings suggest that LDH production of pyruvate
is higher in old SIRT6-tg mice, potentially due to higher NAD+
levels (Fig. 5f). The lactate/pyruvate ratio can be used as a proxy
for the cytosolic NADH/NAD+ ratio56. Indeed, [U-13C]-lactate
injection led to increased lactate[M+ 3]/pyruvate[M+ 3] and
total lactate/pyruvate ratios with advanced age, while remaining
significantly lower in old SIRT6-tg livers (Fig. 6f, g). These results
suggest that SIRT6 preserves a lower cytosolic NADH/NAD+
ratio at old age, which drives the lactate-to-pyruvate direction of
LDH reaction. To test this hypothesis, we injected pyruvate to old
WT and SIRT6-tg mice, thus bypassing LDH reaction, and
measured blood glucose. Interestingly, in contrast to lactate
(Fig. 3c), no difference in GNG capacity from pyruvate was
observed between genotypes (Fig. 6h). In addition, no differences
in the ratios of malate[M+ 2]/malate[M+ 3] and aspartate[M+
2]/aspartate[M+ 3] were found between age or genotypes
(Supplementary Fig. 7f), suggesting that relative pyruvate
carboxylase (PC) flux is not altered, but rather the upstream
LDH-redox effect is prominent. Thus, maintenance of young-like
redox balance by SIRT6 likely activates LDH towards lactate
oxidation resulting in young-like lactate oxidation which enables
maintenance of TCA cycle and gluconeogenic capacity at old age.
SIRT6 promotes hepatic gluconeogenesis via increased lipo-
lysis in adipose tissue. GNG is regulated through both hepatic
and extrahepatic mechanisms13. To determine whether SIRT6
also affects GNG and normoglycemia through extrahepatic
mechanisms, liver-specific SIRT6-tg mice were generated and let
to age (Supplementary Fig. 8a). In comparison to WT mice,
whole-body SIRT6 overexpression mice have higher GNG capa-
city from lactate, increased hepatic GNG gene expression, and
higher levels of key hepatic GNG-related metabolites (Figs. 3c, 4e,
and 5c). However, liver-specific SIRT6-tg and control mice
showed similar blood glucose levels after lactate injection, both at
young and old ages (Fig. 7a and Supplementary Fig. 8b). In
addition, liver-tg and control mice showed similar expression
levels of key hepatic GNG genes, together with similar and even
somewhat reduced levels of hepatic GNG-related metabolites
(Fig. 7b, Supplementary Fig. 8c, and Supplementary Table 9).
These findings show that increased SIRT6 activity in extrahepatic
tissues is necessary to activate GNG, and emphasize the impor-
tance of SIRT6 in synergizing multiple tissues to promote GNG.
Differences in hormonal regulation or alterations in GNG
precursor availability are two possible mechanisms underlying the
extrahepatic effect of whole-body SIRT6 overexpression on GNG.
No differences were found in insulin, glucagon, and corticoster-
one levels, the three known GNG regulators, between old WT and
whole-body SIRT6-tg mice, at different fasting time points
(Supplementary Fig. 8d). In addition, no difference in glucose-
stimulated insulin secretion (GSIS) was observed between old WT
and SIRT6-tg mice (Supplementary Fig. 8e). These results
indicate that the effect of SIRT6 on GNG is not mediated by
change in extrahepatic hormonal regulation.
A second extrahepatic mechanism that can activate GNG is
substrate shuttling to the liver. The circulating levels of the GNG
precursors lactate and pyruvate decreased with age in WT mice,
Fig. 5 Youthful-like hepatic TCA cycle, GNG, and redox metabolite levels in old SIRT6-tg. a Lists of statistically significant metabolites from each of the
four comparisons shown were used to create Venn diagram. The number of significant metabolites in each comparison is shown in parentheses. b PCA of
significantly changed metabolites. Each dot represents one biological replicate. c Heatmap of significantly changed metabolites. Each square represents
average metabolite abundance of n= 5 mice per genotype. TSP, transsulfuration pathway; Y, young; O, old; WT, wild type; TG, transgenic. d–f Scatterplots
showing metabolite levels of hepatic glycolysis/GNG (d), TCA cycle (e), and redox metabolism (f) pathways. n= 5 mice per genotype, each dot represents
one mouse. g Expression of key NAD+ de novo synthesis genes in the liver of young and old WT and SIRT6-tg mice. Asterisks indicate values significantly
different between WT and SIRT6-tg at the same age. n= 8 mice for young WT, young SIRT6, and old SIRT6 (for Haao in young SIRT6, n= 7); and n= 7
mice for old WT (for Nmnat1, n= 8), males. RQ, relative quantity. h Protein levels of NMNAT1 (n= 5 mice) and TDO2 (n= 7 mice) in livers of old WT and
SIRT6-tg littermates. ImageJ quantification of NMNAT1 normalized to α-tubulin and TDO2 normalized to ponceau is shown in the right. For all panels, mice
were at the ages of 5–7 months (young) and 20–24 months (old). Bars represent mean ± SEM. For (d–g) data were analyzed using two-way ANOVA, for
(h) using two-tailed Student’s t-test. Exact p-values are reported in the Source Data file. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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but not in SIRT6-tg mice (Fig. 7c). Similarly, in WT mice, the
levels of the liver GNG precursors lactate, pyruvate, and glycerol
also decreased with age (Fig. 5c and Supplementary Fig. 6c).
During fasting, glycerol and FFAs are released from adipose tissue
as lipolysis products and glycerol is used for GNG in the liver. In
addition, FFAs themselves can also stimulate hepatic GNG57. In
comparison to fasted WT mice, 15 months old SIRT6-tg
littermates have higher circulating glycerol levels (Fig. 2c). Thus,
we hypothesized that in old age, SIRT6 enhances lipolysis and
glycerol release from adipose tissue, contributing to increased
substrate availability for GNG in the liver. Plasma glycerol levels
in 6 h-fasted WT mice decreased with age. Yet, strikingly, old
SIRT6-tg mice showed young-like plasma glycerol levels (Fig. 7c).
Moreover, the active phosphorylated form of the key lipolytic
enzyme, hormone-sensitive lipase (HSL), in the adipose tissue,
increased in old SIRT6-tg mice (Fig. 7d). Old SIRT6-tg mice also
showed higher levels of 16 h-fasted serum FFAs (Supplementary
Fig. 8f). These findings show that enhanced lipolysis and glycerol
release from adipose tissue likely contribute to normoglycemia in
aged SIRT6-tg mice.
Altogether, SIRT6-tg mice maintain young-like energy home-
ostasis at old age. This occurs by increasing systemic GNG
substrate availability and supporting their hepatic utilization by
enhancing de novo synthesis of NAD+, a key modulator of
healthy aging.
Discussion
SIRT6 was previously shown to extend lifespan in male mice and
improve health parameters in aged CB6 mixed-background
animals29,30. Yet, essential questions about the broad effect of
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Fig. 6 SIRT6 restores the significant reduction in hepatic lactate oxidation and contribution to GNG at old age. a Schematic showing fates of lactate
carbons following injection of [U-13C]-lactate, after one round of the TCA cycle or flux through pyruvate carboxylase (PC, Pyr→OAA). White balls, 12C
carbons. Colored balls, 13C carbons. Red, carbon flux from lactate to glucose via the TCA cycle. Yellow, carbon flux from lactate to glucose via PC. b Hepatic
glucose isotopologues, 15 min after [U-13C]-lactate injection. c–e, Relative abundance of hepatic glucose [M+ 2] and glucose [M+ 3] (c), the TCA cycle
metabolites αKG [M+ 2], succinate [M+ 2] and malate [M+ 2] (d), and total pyruvate and pyruvate [M+ 3] (e) 15 min after [U-13C]-lactate injection.
Metabolite peak area values were normalized to total ion count. f, g Hepatic lactate [M+ 3] / pyruvate [M+ 3] peak area ratio (f), and ratio of total liver
metabolite levels of lactate/pyruvate (g) 15min after [U-13C]-lactate injection. For (b–g), mice were at the ages of 5–7 months (young) and 20–24 months
(old). n= 5 mice; bars represent mean ± SEM. One-way ANOVA with Fisher’s LSD method. Exact p-values are reported in the Source Data file. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001. h Pyruvate tolerance test in 20 months old 6 h-fasted WT (n= 7 mice) and SIRT6-tg (n= 6 mice) male mice.
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sex dependent? How does SIRT6 promote healthy lifespan at the
biochemical and molecular levels? And finally, how many tissues
must overexpress SIRT6 to achieve these health improvements? To
address these issues, we followed the effect of SIRT6 overexpression
in inbred C57BL/6JOlaHsd mice. Here, we show that male and
female C57BL/6JOlaHsd mice overexpressing SIRT6, but not SIRT1,
live significantly longer than WT littermates. SIRT6-tg mice main-
tain young-like physical activity and metabolic flexibility, along with
reduced aging-related pathologies. Moreover, further analyses
showed that old SIRT6-tg mice show a young-like liver metabolite
profile. Notably, SIRT6 enables energy production under limited
energy conditions, such as fasting and aging. To mediate this
function, SIRT6 promotes hepatic β-oxidation, lactate and glycerol
shuttling and hepatic utilization, NAD+/NADH ratio in the liver,
and glycerol release from adipose tissue. These SIRT6-regulated
metabolic pathways coordinate to maintain young-like TCA cycle
and GNG activities in old age (Fig. 7e). Thus, the positive effect of
SIRT6 on healthy lifespan is strain and sex independent and requires
SIRT6 regulation of energy production in at least two sites, liver and
adipose tissues. Together, this emphasizes the potential of SIRT6-
based therapeutic approaches in addressing age-related frailty and
other diseases.
Previously, we showed that SIRT6 levels increase under fasting
or CR20, suggesting a role for SIRT6 in regulating aging. Yet,
animals in the wild usually die young, before aging occurs58.
Hence, from an evolutionary perspective, natural selection likely
does not directly influence aging. Therefore, SIRT6 most likely
did not evolve as a regulator of aging, and the increase in its level
upon fasting should be explained. Here, we show that during
fasting, SIRT6 enables better production of energy, suggesting the
evolutionary basis for the increase in SIRT6 levels upon limited
availability of energy sources. Moreover, as seen in Fig. 3, glucose
production capacity significantly decreases with age, an effect
mitigated by increased SIRT6. Interestingly, Gorbunova and
colleagues recently suggested a positive correlation between
SIRT6-dependent DNA repair capacity and rodent lifespan59.
Thus, it would be of great interest to examine the correlation
between SIRT6-dependent energy production capacity and life-
span across evolution.
In addition to whole-body SIRT6 overexpression and deletion,
several SIRT6 tissue-specific models were described. Adipose-
specific SIRT6 deletion promotes insulin resistance60, HFD-
induced obesity, inhibits lipolysis61, and impairs brown adipocyte
thermogenic function62. In addition, increasing adipose SIRT6
levels using viral injection increases ATGL expression, suggesting
higher lipolysis61. Liver-specific deletion of SIRT6 in mice results
in significant metabolic alterations, such as increased triglyceride






















































































































Fig. 7 Enhanced adipose tissue-derived glycerol contributes to maintenance of normoglycemia in aged SIRT6-tg mice. a Lactate tolerance test in
22–24 months old liver-specific SIRT6-tg and appropriate littermate control male mice. Values are mean ± SEM of n= 6 WT mice, n= 5 lox mice, n= 9
Alb-cre mice and n= 5 liver SIRT6-tg mice. Two-way ANOVA showed no difference between liver SIRT6-tg and controls. Bars represent mean ± SEM. b
Heatmap of GNG-related hepatic metabolites in 23–25 months old liver SIRT6-tg male mice and control littermates. Each square represents average
metabolite abundance of n= 5 mice per genotype. See Supplementary Table 9 for source data. c Levels of the GNG precursors glycerol, lactate and
pyruvate in the plasma of 6 h-fasted young (5–7 months) and old (20–24 months) mice, n= 5, males. Box extends from the 25th to 75th percentiles, line in
the middle of the box is the median and whiskers go down to the smallest value and up to the largest. d Western blot and ImageJ quantification of HSL
phosphorylation on Ser563 in white adipose tissue of 25 months old WT and SIRT6-tg littermates. n= 4 mice per genotype. Bars represent mean ± SEM,
two-tailed Student’s t-test. For (c, d), exact p-values are reported in the Source Data file, *p < 0.05. e Schematic model depicting how SIRT6 improves
longevity and healthspan by preserving NAD+ metabolism and energy production pathways in old age. Hepatic TCA cycle and GNG deteriorates during
aging, leading to perturbed energy homeostasis and fasting glycemia in old age. SIRT6 overexpression increases hepatic energy production from fatty acids
and AAs in the liver. This potentially spares GNG substrates, such as lactate and glycerol, whose shuttling during fasting from skeletal muscle and adipose
tissue to the liver is increased by SIRT6. This cascade of events leads to preserved hepatic glucose production in old age. TG, triglyceride; HSL, hormone-
sensitive lipase; DHAP, dihydroxyacetone phosphate; AAs, amino acids; Oxphos, oxidative phosphorylation.
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related phenotypes are consistent with our study, the reports
regarding the effect of liver-specific SIRT6 deletion or over-
expression on GNG are less clear. Dominy et al. showed that mice
with shRNA ablation or adeno-viral overexpression of SIRT6
exhibit induction or inhibition of GNG, respectively36. In con-
trast, Deng and his colleagues reported that liver-specific SIRT6
deletion has no effect on GNG34, and our results show no dif-
ference in GNG from lactate at old age, and modest GNG inhi-
bition at young age, in liver-specific SIRT6-tg mice (Fig. 7a and
Supplementary Fig. 8b). Here, we show that whole-body SIRT6
overexpression promotes GNG from lactate and glycerol in aged
mice. This emphasizes the requirement for additional tissue/s,
besides the liver, in the process of SIRT6-mediated GNG induc-
tion. Indeed, in whole-body SIRT6 overexpression mice there is
an increase in glycerol release from adipose tissue, which is used
for GNG in the liver. This effect, together with our glycerol and
lactate tolerance tests and lactate tracing results (Figs. 3 and 6)
suggest a model where overexpression of SIRT6 both in the liver
and adipose tissues is required for GNG induction.
Aging is often accompanied by a significant increase in
frailty63. Individual frailty is based on five key areas: unintended
weight loss, exhaustion, weakness, slow walking speed, and low
physical activity63. Metabolic dysfunction, particularly in the
ability to produce energy, is a major underlying mechanism of
this syndrome. In addition to FFA β-oxidation, two primary
SIRT6-dependent energy production pathways were identified
here, the activation of TCA cycle and GNG. Interestingly, like
SIRT6-tg mice, CR mice or rhesus monkeys also showed evidence
for increased GNG46,64,65. Increased GNG along with these
energy production pathways affects various aspects of healthy
aging, primarily the capacity for physical activity66,67. In addition,
a healthy metabolic state positively influences memory and sleep
quality, which decline with age68.
The expression of the key hepatic GNG genes Pck1 (encoding for
PEPCK protein), Pcx, G6pc, and Fbp1 were higher in SIRT6-tg
livers (Fig. 4e). Likewise, the levels of PEPCK significantly increased
in CR mice69. This suggests that PEPCK is a key regulator of
longevity and is potentially involved in preserving physical activity
in old age. Indeed, a set of previous observations support this
model. PEPCK knockdown or overexpression, reduces or increases
C. elegans lifespan, respectively70,71. Moreover, PEPCK over-
expression restores locomotor activity in old worms71. Thus, SIRT6
increases GNG capacity in parallel to normal glucose tolerance,
promoting healthy aging of the liver and the organism. These
findings suggest targeting GNG capacity with age as a therapeutic
approach for the treatment of age-related frailty.
It is fascinating that SIRT6 also supports energy production
through additional pathways. SIRT6 increases mitochondrial
biogenesis (Fig. 4e), and NAD+ levels (Fig. 5f). In comparison to
WT mice, mtDNA copy number was significantly higher in
transgenic mice. The increased mitochondria number is poten-
tially due to increased PGC1α levels (Fig. 4e). Yet, PGC1α might
not be the sole contributor to increased mitochondria biogenesis,
since increased PGC1α was found only in old transgenic mice.
Yet, two major lines of evidence support increased PGC1a activity
in young SIRT6-tg mice: first, we found a significant increase in
mitochondrial copy number and second, PGC1α is a major
activator of PPARα. Indeed, PPARα-dependent transcription, and
β-oxidation, a PPARα-dependent pathway, were significantly
higher in young SIRT6-tg mice. Thus, the potential activation of
PGC1α activity in whole-body SIRT6 overexpression should be
further explored.
Hepatic mRNA expression analysis showed that increased
SIRT6 results in a repressed inflammatory signature, especially in
males. These findings are in agreement with the well-documented
anti-inflammatory role of SIRT631. Interestingly, we found an
increase in hepatic essential PUFA levels (Supplementary Fig. 6h),
which are used by the liver as fuel and for anti-inflammatory
signaling72. Thus, this suggests a mechanism underlying the anti-
inflammatory function of SIRT6.
SIRT6 overexpression significantly enhances lifespan of both
sexes in the inbred C57BL/6JOlaHsd mice. Yet, when over-
expressed in mixed-CB6 background, SIRT6 led to lifespan
extension only in males29. Two potential mechanisms can be
suggested for this difference. First, while in CB6, SIRT6 over-
expression lowered circulating IGF-1 levels only in males29, here
serum IGF-1 was decreased by SIRT6 in both sexes (Supple-
mentary Fig. 1i). Given the fundamental role of insulin/IGF-1
pathway in lifespan regulation6, this may be a prominent effect.
Interestingly, SIRT6’s lifespan extension was stronger in males
than in females (Fig. 1a). Accordingly, circulating IGF-1 levels are
lower in WT females relative to WT males (Supplementary
Fig. 1i). This masks the beneficial effect of SIRT6 on females’
lifespan via IGF-1. Second, weight maintenance at old age is
associated with increased survival in mice and humans38,39.
Interestingly, here, SIRT6 led to improved weight maintenance in
females (Supplementary Fig. 1d, f). Thus, one can suggest that
female-specific better weight maintenance contributes to SIRT6-
dependent lifespan extension in females. Since in CB6 mice, this
parameter was not followed longitudinally in our previous study,
future research is required to examine weight maintenance in
CB6 background as well.
SIRT6 had a milder effect in females in additional parameters,
such as treadmill endurance running and liver transcriptional
profile (Fig. 4a and Supplementary Fig. 2i, j). Endurance activity
is an energy-demanding process. Thus, the improved endurance
performance in males might be due to their stronger activation of
the GNG and β-oxidation energy production pathways by SIRT6
(Figs. 3 and 4b). In comparison to young females, young male
mice show a robust SIRT6-mediated hepatic transcriptional
profile. This change is largely related to a higher basal inflam-
matory state in males, which is inhibited by SIRT6 (Fig. 4b).
Interestingly, in humans, males are more susceptible to chronic
inflammatory diseases than women prior to menopause73.
Therefore, this might also contribute to the stronger SIRT6-
dependent lifespan extension observed in males. Moreover, all
these can also explain the stronger SIRT6 effect on lifespan in the
current genetic background.
Liver NAD+ levels were significantly higher in old SIRT6-tg
mice. This could be due to increased production or reduced
utilization of NAD+. In addition, SIRT6-tg mice showed a sig-
nificant increase in the levels of NAM, a reaction product of
SIRT6. Increased NAM levels, suggest that NAD+ utilization by
SIRT6 increases. Yet, as seen in Supplementary Fig. 6j, a reduced
NAD+ usage by other consumers, due to reduced DNA damage
or PARP1 activity was excluded. Increased NAM levels can
support the increased NAD+ levels via two pathways. First,
within the NAD+ salvage pathway, NAM can be used as a direct
NAD+ precursor. Yet, no significant change in the levels of
NAMPT, a key enzyme of NAD+ salvage, was found between WT
and SIRT6-tg mice (not shown). Thus, increased NAM probably
does not support the increased NAD+ levels via the salvage
pathway. Second, recently, Mitchell et al. showed that increased
NAM levels induces the NAD+ de novo synthesis pathway53.
Indeed, the expression and protein levels of major enzymes in the
de novo synthesis pathway were significantly higher in SIRT6-tg
mice (Fig. 5g, h). Thus, we suggest that SIRT6 promotes de novo
NAD+ synthesis, which can be used by various mediators of
healthy aging such as other sirtuins and PARP’s under genotoxic
stress.
Interestingly, the SIRT6-mediated increased hepatic NAD+
and cytosolic NAD+/NADH ratio favor the reverse LDH
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reaction. This serves as a central mechanism in GNG main-
tenance in old age by SIRT6, as revealed by hepatic lactate/pyr-
uvate ratios and lactate and pyruvate tolerance tests (Figs. 3 and
6). The increased hepatic GNG gene expression in SIRT6-tg
(Fig. 4e) is not the driving mechanism for GNG activation in
this model.
Altogether, SIRT6 controls lifespan and the ability to generate
energy at times of its limited availability, such as physical activity,
fasting and aging. These pathways, together with SIRT6’s known
regulating role of the key aging-related metabolic signaling
pathways mTOR, IGF-1, and AMPK places SIRT6 as a master
regulator of healthy aging and as a potential therapeutic target to
preserve function and delay the onset of frailty.
Methods
Animal husbandry. All experiments were conducted in accordance with Bar-Ilan
Institutional Animal Care and Use Committee and approved by the Ministry of
Health of Israel. Mice were group housed in IVC cages (up to 5 animals/cage) in a
specific pathogen-free environment and fed standard chow diet (Altromin 1324;
total pathogen free, irradiated with 25 kGy) and water ad libitum. Animal rooms
were maintained at 21–24 °C and 35–75% relative humidity, with 12/12 h (7 a.m. to
7 p.m.) dark–light cycle. Cages were routinely replaced every 10–14 days.
Mice. Transgenic lines were originally generated in hybrid genetic
backgrounds26,74, and were backcrossed for at least 10 generations to C57BL/
6JOlaHsd background before usage. As several lines of SIRT6-tg mice were gen-
erated, it is important to note that all of the mice used in this study were from the
same line (#55) as previously published29. SIRT1+ 6-tg mice were obtained by
crossing SIRT6-tg with SIRT1-tg mice. Further matings were either of WT C57BL/
6JOlaHsd (purchased from Envigo, Israel) with SIRT1+ 6-tg or of SIRT6-tg with
SIRT1-tg. Mice overexpressing SIRT6 specifically in the liver were obtained by
crossing Alb-cre mice (Jax Stock No: 003574) with lox-stop-lox SIRT6-knockin
mice (Described in Figure S7A). To avoid potential epigenetic effects of the
transgenes, progenies were obtained by alternate matings of male from one gen-
otype with female from the other genotype and vice versa. At the age of 1 month,
progenies were separated by sex, ear tagged, and distal tail (~2 mm) was cut for
genotyping determination. WT and transgenic mice were housed in the same cage,
and for all experiments, only littermates were compared. Throughout the study, if
not stated otherwise, mice at the ages of 4–7 months were considered as young, and
mice at the ages of 20–25 months were considered old. Mice with visibly unhealthy
appearance were not used for in vivo experiments or for tissue collection.
Lifespan. For lifespan study, mice were housed as described in “Animal husban-
dry” section and were left undisturbed in cages until natural death. These animals
were not used for any other experiment and were virgins, the only procedure they
underwent was the standard ear-tagging and 2 mm tail cutting for genotyping at
1 month of age. Other cohorts where raised for in vivo experiments and tissue
collections. Mice were inspected daily for health issues, and any death was recor-
ded. Animals showing significant signs of morbidity, based on the AAALAC
guidelines, were euthanized for humane reasons, and were used for lifespan ana-
lysis since they were deemed to live to their full lifespan. No mice were censored
from analysis. Lifespan was analyzed by Kaplan–Meier survival curves, and p-
values were calculated by log-rank test using SPSS (version 20, IBM). Maximum
lifespans and 20th percentiles were calculated as the proportion of each group still
alive when the total population reached 90% or 20% mortality, respectively, and
significance was analyzed with Fisher’s exact test.
Histopathology. Histopathological analysis was performed on two separate mouse
cohorts. The first cohort were mice sacrificed at age of 25 months by CO2 inha-
lation. From ~10 tissues, healthy-appearing part was taken into liquid nitrogen for
protein/RNA extraction, and the remaining tissue parts together with the mouse’s
backbone were transferred to 4% neutral formalin for histopathological analysis.
The 2nd cohort was end-of-life examination (not from the cohort used for life-
span). Old animals found moribund, soon before estimated natural death, were
used; in that case they were euthanized and tissues were fixed. Mice found after
death could not be used for analysis due to poor quality of tissues.
Tissue samples were fixed in 4% neutral formalin, embedded in paraffin,
sectioned 3 µm thick, and dried. Slides were de-waxed and re-hydrated through a
series of graded ethanol and were stained with hematoxylin-eosin (H&E).
Photographs were taken using an Olympus DP73 digital camera, and analyzed by
an expert pathologist in a blinded fashion with respect to the genotypes of the
analyzed samples.
Any of the following pathologies was considered as neoplasia: hyperplasia,
lymphoma, sarcoma, hemangiosarcoma, hemangioma, adenoma, or carcinoma.
Either lymphoma, sarcoma, hemangiosarcoma, or carcinoma were defined as
cancer.
Tissue and plasma collection. In all cases, mice were sacrificed between 2 p.m.
and 4 p.m. to avoid any potential circadian effects on downstream analysis. For
protein, RNA and DNA extraction, tissues were collected from mice fasted for 4 h
(~10 a.m.–2 p.m.) and sacrificed by CO2 inhalation. Tissues were collected quickly
(~5 min/mouse), and immediately snap-frozen in liquid nitrogen and stored at
−80 °C prior to use. For liver metabolomics, mice fasted for 6 h (~8 a.m.–2 p.m.) or
mice 15 min after [U-13C]-lactate injection (at ~3 p.m.) were sacrificed by cervical
dislocation. Tissues were collected rapidly (~2 min/mouse for most tissues, liver
was collected in ~30 s), snap-frozen in liquid nitrogen, and stored at −80 °C prior
to use. For the analysis of plasma metabolites, ~30 µl of blood was drawn from tail
bleeds into heparin-coated tubes immediately before mice’s sacrifice. Blood was
centrifuged for 10 min at 2000g at 4 °C, plasma was transferred to new tube, snap-
frozen in liquid nitrogen, and kept at −80 °C until use.
Western blotting. Tissue homogenization was performed using the Bullet Blender
homogenizer (Next Advance) in ice-cold lysis buffer (10 mM TrisHCl pH 7.4, 150
mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% TritonX100, 7 M urea, 2 mM vana-
date, 2.5 mM sodium pyrophosphate, 10 mM NaF, proteinase inhibitor cocktail pill
[Santa Cruz Biotechnology]). Samples were centrifuged at 17,000g for 5 min at 4 °C
to remove undissolved tissue debris, supernatant was collected, and centrifuged
again at the same conditions to get rid of undissolved fat. The clear supernatant
was collected and protein concentration was determined with Bradford protein
assay (Bio-Rad). Samples were boiled with sample buffer for 7 min and equal
amount of protein were run in polyacrylamide gels. Transfer was performed using
Trans-Blot Turbo System and 0.2 µm nitrocellulose membrane (Biorad). Mem-
branes were blocked for 1 h with 5% BSA and incubated overnight at 4 °C with
primary antibody directed against β-actin (C4, sc-47778, at 1:1000 dilution), Ub
(P4D1, sc-8017, 1:1000), PARP1 (F-2, sc-8007, 1:1000), α-tubulin (Sigma Aldrich
clone B-5-1-2, T5168, 1:7000), SIRT6 (D8D12, cst-12486, 1:1000), PSMB5 (β5)
(D1H6B, cst-12919, 1:1000), PSMB8 (β5i) (D1K7X, cst-13635, 1:1000), LC3B (cst-
2775, 1:1000), p62 (cst-5114, 1:1000), HSL (D6W5S, cst-18381, 1:1000), phospho-
HSL (ser 563) (cst-4139, 1:1000), phospho-Histone H2A.X (Ser139) (Milli-
poreSigma clone JBW301, #05-636, 1:200), PAR (Trevigen, 4335-AMC-050,
1:1000), NMNAT1 (ab45652, 1:1000), and TDO2 (LSBio, LS‑C748245, 1:500).
Anti-mouse or anti-rabbit HRP-conjugated antibodies (Jackson ImmunoResearch,
115-035-146 and 111-035-003, 1:15000) were used as secondary antibodies. Bands
were detected using Clarity™ Western ECL Substrate (Biorad) with pictures cap-
tured in Amersham Imager 680 (GE Healthcare). Quantification was performed by
densitometric analysis using ImageJ software and normalization to α-tubulin, β-
actin, or Ponceau S staining (Sigma-Aldrich).
RNA extraction and quantitative real-time PCR. Liver tissues snap-frozen in
liquid nitrogen upon dissection and further stored at −80 °C were cut to ~30 mg
piece on dry ice, and homogenized with plastic pestles or in Precellys® Tissue
Homogenizer in TRI Reagent (Sigma-Aldrich). RNA was extracted according to
manufacturer’s specifications. RNA purity and concentration were assessed using a
Thermo Fisher Scientific 2000 spectrophotometer (Thermo Fisher Scientific), and
1–3 µg were taken for cDNA synthesis (iScript™ Advanced cDNA Synthesis Kit,
Biorad). The quantitative PCR was carried out using iTaq™ Universal SYBR® Green
Supermix (Biorad) in a 15 µl total volume reaction containing 3 µl of 1:30 diluted
cDNA. PCR amplification was performed using a StepOnePlus instrument
(Applied Biosystems) or with CFX96 Real-Time-PCR detection system (Bio-Rad),
and gene expression was normalized to Actb expression. The list of primers used
for real-time PCR is given in Supplementary Table 10.
Serum metabolomics. For serum metabolomics, we used male mice at age of
15 months. Blood was collected from facial vein of mice in the fed state, and then
after 4 and 16 h fasting. Fed state was at Zeitgeber time 23, ~6 a.m., which is near
the end of the mice’s normal feeding period. Mice were subsequently transferred to
a new cage without food but with free access to water for up to 16 h. Blood was
allowed to clot for 30 min at room temperature and centrifuged at 2000 g for 10
min at 4 °C to separate the serum. Collected serum was snap-frozen in liquid
nitrogen and stored at −80 °C until later use. Metabolomics analysis was per-
formed by gas chromatography time-of-flight mass spectrometry (GC-TOF-MS) in
the UC Davis West Coast Metabolomics Center with the following procedure. First,
20 µl serum was mixed with 1 ml of extraction mix containing acetonitrile, iso-
propanol, and water in proportions 3:3:2 (JT Baker, Center Valley PA), then
vortexed for 10 s and then 6 min at 4 °C. Samples were next centrifuged for 2 min
at 14,000 g, 500 µl extract was transferred to a new tube and dried via evaporation
overnight using speed vacuum concentration system (Labconco, Kansas City MO).
The dried tube was resuspended in 500 µl of 50% acetonitrile, vortexed for 10 s, and
centrifuged for 2 min at 14,000 g. Then, 475 µl extract was moved to a new tube
and dried via evaporation as before. Samples were then derivatized by methox-
yamine hydrochloride in pyridine and subsequently by N-methyl-N-trimethylsi-
lyltrifluoroacetamide. Data acquisition was performed as previously published45,75.
Briefly, the column used was Restek Corporation Rtx-5Sil MS (30 m length ×
0.25 mm ID with 0.25 μm film made of 95% dimethyl/5% diphenylpolysiloxane)
protected by a 10 m long empty guard column. MS parameters are used as follows:
a Leco Pegasus IV mass spectrometer is used with unit mass resolution at
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17 spectra/s from 80 to 500 Da at −70 eV ionization energy and 1800 V detector
voltage with a 230 °C transfer line and a 250 °C ion source. Injection volume was
0.5 μl with10 μl/s injection speed and helium mobile phase. ChromaTOF version
2.32 software was used for data preprocessing without smoothing, 3 s peak width,
baseline subtraction just above the noise level, and automatic mass spectral
deconvolution and peak detection at signal/noise levels of 5:1 throughout the
chromatogram. Apex masses are reported for use in the BinBase algorithm.
Quantification is reported as peak height using the unique ion as default. Raw data
were normalized to the sum of all peak heights for all identified metabolites, but
not the unknowns, for each sample, and differences between groups where further
analyzed using GraphPad prism software. Raw metabolomics MS data were
deposited to NIH Common Fund’s National Metabolomics Data Repository
(NMDR) website, the Metabolomics Workbench, https://www.
metabolomicsworkbench.org where it has been assigned Project ID PR001005. The
data can be accessed directly via its Project https://doi.org/10.21228/M8SH6G.
Blood parameters. For blood hematology parameters, whole blood was taken from
tail bleedings into EDTA-coated tubes and sent on ice for analysis at AML
laboratories, Israel. Complete blood count was performed by Sysmex XS-1000i
hematology analyzer, and differential count of white blood cells was performed
manually by a veterinary in a blinded manner with respect to genotypes. For serum
chemistry, blood was derived from facial vein of 3 h-fasted mice, except for total
cholesterol and HDL that in old mice were analyzed in blood derived from heart
puncture of 4 h-fasted mice. Blood was allowed to clot for 30 min at room tem-
perature, centrifuged at 2000 g for 10 min at 4 °C to separate the serum and sent to
AML laboratories, Israel, where serum biochemistry parameters were analyzed
using Cobas 6000 automated analyzer (Roche Diagnostics). LDL levels were cal-
culated by subtracting HDL levels from total cholesterol levels. Serum IGF-1 levels
were determined using IGF-1 ELISA Kit (R&D Systems) following the manu-
facturer’s instructions.
Transcriptomics. RNA was extracted using TRI Reagent (Sigma-Aldrich) and
extraction quality was evaluated using Tapestation RNA Assay (Agilent Technol-
ogies, CA, USA). Libraries were prepared with the NEBNext Ultra RNA library
prep Kit (#E7530, NEB) using manufacturer’s instructions, and final evaluation of
library integrity was carried out with Tapestation DNA HS Assay (Agilent Tech-
nologies, CA, USA). Equimolar pooling of libraries were performed based on Qubit
quantification, and loaded onto an Illumina Hiseq 2500 platform (Illumina, CA,
USA). Libraries were sequenced in a multiplexed fashion using single-end
sequencing protocol, yielding 24–47 million reads per sample. Reads were aligned
to mouse genome (mm10) using the STAR RNA-seq aligner software (version
STAR_2.5.0a)76. The STAR genome database was built with the Gencode anno-
tation file (vM12). Only uniquely mapped reads (20–36 million reads per sample)
were considered for further analysis. Raw read counts for 49585 Gencode-
annotated gene-level features were determined using HTSeq-count77. Differentially
expressed genes were determined with the R Bioconductor package DESeq278, and
p-values were corrected with Benjamini-Hochberg false discovery rate (FDR)
procedure. For the analysis of predicted upstream regulators (Fig. 4d), we used
Ingenuity Pathway Analysis software79 using input gene lists with fold change
cutoff ±1.5 with FDR q-value < 0.1 for males and FDR q-value < 0.25 for females,
yielding 2880 and 184 differentially expressed genes in males and females,
respectively.
For pathway analysis, we used Gene Set Enrichment Analysis (GSEA)80. We
uploaded expression dataset gene list containing 21,575 genes which were defined
as expressed genes, these genes had minimal normalized mean read count of 0.5
reads/gene. Analysis was performed using the stringent option of 1000
permutations.
Metabolic cages and treadmill running. In vivo metabolic performance and
physical activity were measured with automated indirect calorimetry system (TSE
Systems GmbH) using animals at the indicated age and sex. Mice were individually
housed in home cages and were allowed to acclimate for 24 h. Then, food and water
consumption, oxygen consumption (VO2), carbon dioxide production (VCO2),
respiratory exchange ratio (RER), and spontaneous home cage activity were con-
tinuously recorded for 72 h. Spontaneous home cage activity is monitored using an
infrared light-beam frame which records beam interruptions in the x–y axis. After
the 72 h period, a running wheel was added to each cage and running distance,
running time, average and max speed on wheel, were recorded for another 72 h
period, of which the first 24 h were considered as acclimation period and not
included in analysis. For treadmill running assay, mice were first acclimated to the
treadmill for 3 constitutive days for 5 min at a speed of 5 m/min. At the 4th day, an
incremental protocol was used: treadmill speed began at 5 m/min and was
increased to 8 m/min after 2 min. Thereafter, the speed was increased at a rate of
2 m/min every 2 min and the distance (m) and time (min) to exhaustion, as defined
by unwillingness to move along the treadmill for at least 5 s albeit stimulation of
mild electric shock, were determined. The formula to determine the amount of
work (J) performed was: J=mass (kg) × g (9.8 m/s2) × distance (m) × sin(θ) (with
an incline of θ= 5°).
Measurements of blood glucose during fasting. Blood glucose was measured by
tail bleeds using glucometer test strips (Abbot). Few microliters of blood were
drawn from the same individual mice at fed state, and at 4, 8, 12, 16, and 24 h of
fast. Mice had free access to water along the experiment. Fed state was at Zeitgeber
time 23, ~6 a.m.
Intraperitoneal lactate, glycerol pyruvate, and glucose tolerance tests. Sodium
L-lactate (Spectrum Chemicals), glycerol and sodium pyruvate (Sigma-Aldrich)
were prepared as 0.1 mg/µl in PBS, glucose was prepared as 20% w/v in PBS, and
were filtered with 0.2 µm filter. Mice at the indicated age and sex were fasted for 6 h
(8 a.m.–2 p.m.) for lactate, glycerol, and pyruvate tolerance tests, or 16 h overnight
for glucose tolerance test, weighted, and ~1 mm of tail end were cut with sterile
scalpel. Blood glucose levels were measured by tail bleeding before or at the
indicated time points after lactate, glycerol, pyruvate (all 1 g/kg body weight), or
glucose (2 g/kg body weight) intraperitoneal injection using glucometer test strips
(Abbot) by observer blinded to animal genotype. Animals had free access to water
during the whole experiment.
Glucose-stimulated insulin secretion (GSIS). Mice were injected intraper-
itoneally with 2 g/kg glucose, and ~20 µl of blood were withdrawn from tail
bleeding before and at the indicated time points after injection. Serum was sepa-
rated and kept at −80 °C until analysis. Insulin levels in serum samples were
measured with ultra-sensitive mouse insulin ELISA kit (Crystal Chem) following
the manufacturer’s instructions.
Body composition measurements. Body composition was measured by nuclear
magnetic resonance (NMR) using the Minispec LF90 (Bruker Optics, Billerica,
MA). Lean and fat mass were recorded.
Hepatic glycogen measurement. Liver glycogen was measured using Glycogen
Assay Kit (Sigma-Aldrich, MAK016) following manufacturer’s protocol.
Serum FFA measurement. Serum FFAs were measured using Free Fatty Acid
Quantification Kit (BioVision, K612) following manufacturer’s protocol.
Liver and plasma metabolite measurements. To maximize accuracy and to take
into account tissue inhomogeneity, metabolites were extracted from three separate
liver pieces for each mouse, and the average metabolite value of the three technical
replicates was calculated at analysis. In detail, frozen liver pieces weighting ~30 mg
were transferred into soft tissue homogenizing CK 14 tubes containing 1.4 mm
ceramic beads (Bertin corp.) prefilled with 1 ml of cold (−20 °C) metabolite
extraction solvent (Methanol:Acetonitrile:H2O::50:30:20) and kept on ice. Samples
were homogenized using Precellys 24 tissue homogenizer (3 × 20 s at 6000 rpm,
with a 30 s gap between each of the three cycles, Bertin Technologies) cooled to
2 °C. Homogenized extracts were centrifuged in the Precellys tubes at 18,000 g for
15 min at 4 °C, supernatants were collected in microcentrifuge tubes and cen-
trifuged again at 18,000 g for 10 min at 4 °C. The supernatants were transferred to
glass HPLC vials and kept at −75 °C prior to LC-MS analysis. For the analysis of
plasma glycerol and lactate, plasma was thawed on ice and mixed in 2 °C cooled
Precellys 24 tissue homogenizer (3 × 30 s at 4500 rpm). Plasma was diluted in a
ratio of 1:100 for lactate and pyruvate, or 1:10 for glycerol with cold (−20 °C)
metabolite extraction solvent (Methanol:Acetonitrile::75:25) and mixed again in
Precellys homogenizer (same conditions). Samples were then treated with similar
centrifugations as liver homogenized extracts and kept at −75 °C prior to LC-MS
analysis. Similar to liver, for each plasma sample metabolites were extracted in
triplicate, with the exception of 3 samples that had too small plasma volume, 2 of
them analyzed with 2 replicates and 1 sample that did not have replicates.
LC-MS metabolomics analysis was performed as described previously81. Briefly,
Thermo Ultimate 3000 high-performance liquid chromatography (HPLC) system
coupled to Q-Exactive Orbitrap Mass Spectrometer (Thermo Fisher Scientific) was
used with a resolution of 35,000 at 200 mass/charge ratio (m/z), electrospray
ionization, and polarity switching mode to enable both positive and negative ions
across a mass range of 67–1000m/z. HPLC setup consisted ZIC-pHILIC column
(SeQuant; 150 mm × 2.1 mm, 5 μm; Merck), with a ZIC-pHILIC guard column
(SeQuant; 20 mm × 2.1 mm). Here, 5 µl of Biological extracts were injected and the
compounds were separated with mobile phase gradient of 15 min, starting at 20%
aqueous (20 mM ammonium carbonate adjusted to pH 9.2 with 0.1% of 25%
ammonium hydroxide) and 80% organic (acetonitrile) and terminated with 20%
acetonitrile. Flow rate and column temperature were maintained at 0.2 ml/min and
45 °C, respectively, for a total run time of 27 min. All metabolites were detected
using mass accuracy below 5 ppm. Thermo Xcalibur 4.0 was used for data
acquisition.
TraceFinder 4.1 was used for analysis. Peak areas of metabolites were determined
by using the exact mass of the singly charged ions. The retention time of metabolites
was predetermined on the pHILIC column by analyzing an in-house MS metabolite
library that was built by running commercially available standards. For data
normalization of liver tissues, raw data files were processed with Compound
Discoverer 3.0 to obtain total measurable ions peak area for each sample. Metabolite
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peak area values in each sample were divided by the total ion peak area value
measured in the sample. Raw liver metabolomics MS data were deposited to NIH
Common Fund’s National Metabolomics Data Repository (NMDR) website, the
Metabolomics Workbench, https://www.metabolomicsworkbench.org where it has
been assigned Project ID PR001017. The data can be accessed directly via its Project
https://doi.org/10.21228/M87M4S.
Quantification of mitochondrial DNA. Total DNA was isolated by standard
proteinase K and phenol-chloroform methods. The copy number of mtDNA was
analyzed by quantitative real-time PCR. Of the total DNA, 0.4 ng was used as a
template for the amplification of mtDNA. Product levels from primers against
mouse mtDNA (5′-AAGACACCTTGCCTAGCCACAC-3′ and 5′-TGGCTGGCA
CGAAATTTACC-3′) were normalized against nuclear 18S rRNA gene (5′-AACTT
TCGATGGTAGTCGCCG-3′ and 5′-CCTTGGATGTGGTAGCCGTTT-3′).
Liver proteomics
Sample preparation for LC-MS analysis. In order to remove lipids and detergents
300 μg of mouse tissue lysates from 6 controls and 6 cases were precipitated using
standard methanol/chloroform extraction protocol (sample:methanol:chloroform:
water::1:4:1:3)82. Proteins were resuspended in 30 μl of concentrated urea buffer
(8M urea, 2 M thiourea, 150 mM NaCl (Sigma)), reduced with 50 mM DTT for 1 h
at 36 °C and alkylated with 100 mM iodoacetamide for 1 h at 36 °C in the dark. The
concentrated urea/protein mixture was diluted 12 times with 50 mM ammonium
bicarbonate buffer and proteins were digested for 18 h at 36 °C using trypsin/LysC
mixture (Promega) in 1:50 (w/w) enzyme-to-protein ratio. Protein digests were
desalted on 10 × 4.0 mm C18 cartridge (Restek, cat# 917450210) using Agilent 1260
Bio-inert HPLC system with the fraction collector. Purified peptides were speed
vacuum dried and stored at −80 °C until further processing. Peptides (100 μg) were
labeled with Tandem Mass Tags (TMT 6plex, Thermo Fisher) according to
manufactures instructions. Each TMT labeling reaction contains 6 labels to be
multiplexed in a single MS run. Labeled peptides from 6 different TMT tags were
combined into one experiment and fractionated.
High-pH RPLC fractionation and concatenation strategy. High-pH RPLC fractio-
nation was performed on Agilent 1260 Bio-inert HPLC system using 3.9 mm × 5
mm XBridge BEH Shield RP18 XP VanGuard cartridge and 4.6 mm × 250mm
XBridge Peptide BEH C18 column (Waters). Solvent composition was as follows:
10 mM ammonium formate (pH 10) as mobile phase A and 10 mM ammonium
formate and 90% ACN (pH 10) as mobile phase B83. TMT-labeled peptides pre-
pared from mouse livers were separated using a linear organic gradient (from 5% to
50% B in 80 min). Initially, 80 fractions were collected during each LC run at 1 min
intervals each. Three individual high-pH fractions were merged into 15 master
fractions with the 15 min intervals between each fraction (fraction 1, 16, 31, 46,
61=master fraction 1, fraction 2, 17, 32, 47, 62=master fraction 2, and so on).
Combined fractions were speed vacuum dried, desalted and stored at −80 °C until
final LC-MS/MS analysis.
Nano LC-MS/MS analyses. Purified peptide fractions were analyzed using UltiMate
3000 Nano LC Systems coupled to the Q Exactive HF mass spectrometer (Thermo
Scientific, San Jose, CA). Each fraction was separated on a 35 cm capillary column
(3 µm C18 silica, Hamilton, HxSil cat# 79139) with 150 μm ID on a linear organic
gradient using 550 nl/min flow rate. Gradient went from 5% to 35% B in 90 min.
Mobile phases A and B consisted of 0.1% formic acid in water and 0.1% formic acid
in acetonitrile, respectively. Tandem mass spectra were obtained using Q Exactive
HF mass spectrometer with the heated capillary temperature +280 °C and spray
voltage set to 2.5 kV. Full MS1 spectra were acquired from 300 to 1500m/z at
120,000 resolution and 50 ms maximum accumulation time with automatic gain
control (AGC) set to 3 × 106. Dd-MS2 spectra were acquired using dynamic m/z
range with fixed first mass of 100m/z. MS/MS spectra were resolved to 30,000 with
155 ms of maximum accumulation time and AGC target set to 2 × 105. Twelve
most abundant ions were selected for fragmentation using 30% normalized high
collision energy. A dynamic exclusion time of 40 s was used to discriminate against
the previously analyzed ions.
Bioinformatics analysis. Raw files from LC-MS analysis were converted to mascot
generic format (.mgf) using MSConvert software (ProteoWizard 3.0.6002) and the
spectra were searched with Mascot 2.4.1 and X!Tandem CYCLONE (2010.12.01.1)
against SwissProt mouse sequences from the Uniprot database (version year 2016,
appended with 115 known contaminant proteins). The search parameters were set
as TMT6plex lysine and N-terminus as fixed modifications and variable mod-
ifications of carbamidomethyl cysteine, deamidation of asparagine and glutamate,
carbamylation of lysine and N-terminus, and oxidized methionine. A peptide mass
tolerance of 20 ppm and 0.08 Da, respectively, and two missed cleavages were
allowed for precursor and fragment ions in agreement with the instrument mass
accuracy. Mascot and X!Tandem search engine results were analyzed in Scaffold Q
+ 4.4.6 (Proteome Software, Inc). Peptide and protein probability were calculated
by PeptideProphet and ProteinProphet probability model84,85. The TMT channels’
isotopic purity was also corrected according to the TMT Kit instructions.
Protein results were filtered at 1% thresholds of both protein and peptide FDR
and required at least one unique peptide for protein identification. Those proteins
that were identified from a single peptide were included in further analysis if that
identification was confirmed by more than one search engine (as previously
described) and identified across all samples. Reporter ion intensity quantitative
values were extracted from Scaffold, and decoy spectra, contaminant spectra,
peptide spectra shared between more than one protein and peptides with missing
channel intensities were removed (overall < 2% missing quantification signals). The
log2-transformed relative abundance was then normalized by median subtraction
from all reporter ion intensity belonging to a protein across all channels. Relative
protein abundance was estimated by the median of all peptides for a protein
combined. Protein sample loading effects from sample preparations were corrected
by median polishing, i.e., subtracting the channel median from the relative
abundance estimate across all channels to have a median zero as described
elsewhere86,87. Quantified proteins were clustered together if they shared common
peptides and corresponding gene names were assigned to each protein for
simplified data representation. Each protein from two TMT experiments were
fitted to a linear model and empirical Bayes methods for assessing differential
expression87 between groups. Protein significance (p-values) were calculated by
ordinary t-test and moderate t-test across sample groups. The moderated t-statistic
is the ratio of the log2 expression level of the protein to its standard error. Log fold
expression change over sample groups were calculated and p-value < 0.05 for a
protein was considered as significant. Annotation of the proteins were performed
by manual curation and combining information from Uniprot, GO, and KEGG
database. Further bioinformatics analysis and visualization of the data were
performed using R programming language (3.4.0) and the free libraries available on
Bioconductor.
Statistical analysis. Data are presented as mean ± SEM for bar and line graphs.
For box plots, box extends from the 25th to 75th percentiles, line in the middle of
the box is the median and whiskers go down to the smallest value and up to the
largest. n indicates the number of animals per experimental group, and is reported
in the figures or figure legends. Statistical significance for single comparisons was
calculated with unpaired two-tailed Student’s t-test. One-way or two-way analysis
of variance (ANOVA) with fisher’s LSD method was used for multiple-group
comparisons limited to up to 3 planned pairwise comparisons88. For multiple-
group comparisons containing more than 3 pairwise comparisons, two-way
ANOVA with Dunnett’s or Sidak’s post hoc test was used. For comparisons
containing 3 variables (e.g., age, genotype, time), three-way repeated measures
ANOVA with Sidak’s post hoc test was performed. Histopathology statistics values
were derived with Fisher’s exact test. Pearson correlation coefficients were used to
measure correlations. t-test values were calculated in Microsoft excel, one-way and
two-way ANOVA were calculated with GraphPad prism software version 6.0, and
three-way ANOVA was performed using SPSS (version 20, IBM). Heatmap of
significant metabolites and Metabolite Set Enrichment Analysis (MSEA) was
generated using the web-based MetaboAnalyst 4.0 software89 (https://www.
metaboanalyst.ca/). All comparisons were two-tailed, and p < 0.05 was considered
to be a statistically significant difference. *p < 0.05, **p < 0.01, ***p < 0.001, ****p
< 0.0001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Raw and processed RNA-seq datasets were deposited to NCBI’s GEO database under the
accession number: GSE157838, the data can be accessed using the link. The MS
proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE90 partner repository with the dataset identifier PXD021447, and can be accessed
using the link. All raw metabolomics MS data were deposited to NIH Common Fund’s
National Metabolomics Data Repository (NMDR) website, the Metabolomics
Workbench, https://www.metabolomicsworkbench.org where it has been assigned
Project IDs PR001005 (serum metabolomics) and PR001017 (liver metabolomics). The
data can be accessed directly via its Project DOIs https://doi.org/10.21228/M8SH6G and
https://doi.org/10.21228/M87M4S. Databases used in this study: Uniprot (https://www.
uniprot.org/), GO (http://geneontology.org/) and KEGG database (https://www.genome.
jp/kegg/). Source data are provided with this paper.
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